TRUMBULL, CT--(Marketwired - Oct 1, 2015) - ZetrOZ, Inc. was competitively selected for a Phase II award from the U.S. Army Medical Research and Materiel Command (USAMRMC) to continue the evaluation of sam® (Sustained Acoustic Medicine) to accelerate soft-tissue healing of trauma wounds. sam® is the first wearable, drug-free, ultrasound-based device to stimulate cellular activity and nutrient transfer multiple hours a day, up to 7 days per week. 

The Phase II contract was awarded in accordance with the successful work performed under the Phase I contract. It was demonstrated that daily 4 hour sam® treatment has the ability to accelerate cellular wound healing activity 25% faster than current standards of wound care. Continued work will be performed in collaboration between ZetrOZ and Professor Stephen Davis, Director of the Pre-Clinical Wound Healing & Infection Research Laboratories in the University of Miami Health System. 

"We are very impressed with the results from our initial studies with sam® that showed that this wearable medical device can spur wound healing," said Prof. Davis. "We look forward to our continued investigations in the new Phase II program where we will expand our studies of this innovative device for other types of wounds. These studies may have significant implications for not only wounded military personnel but also for civilians."

"Now that we have validated the ability of sam® to accelerate the natural healing of trauma injuries, our teams will work to develop and deploy innovative wound healing solutions relevant to current military concerns including injuries from IEDs, burns and lacerations," said George K. Lewis Jr., PhD, ZetrOZ President and Chief Executive Officer. "These latest results and partnership with USAMRMC in wound healing opens a new market opportunity for ZetrOZ, and builds upon our existing sam® product portfolio for the non-invasive treatment of pain and accelerating the natural healing cascade for musculoskeletal injuries." 

ZetrOZ, Inc. will be attending the Defense Energy Innovation Summit in Austin, Texas in December 2015 to present the findings from the Phase I research program.

About ZetrOZ, Inc.
ZetrOZ develops wearable bio-regenerative devices for the delivery of sustained acoustic medicine, a new treatment form. Built on a proprietary miniaturized ultrasound platform designed for the treatment of acute and chronic musculoskeletal conditions, ZetrOZ devices are clinically proven to enhance tissue recovery, accelerate the body's natural healing processes, and relieve pain. Since the company's founding in 2009, ZetrOZ has successfully applied this innovative technology to the development of two products now available on the market: sam® Sport, an FDA cleared class II medical device, and UltrOZ™ Elite for the maintenance and rehabilitation of competitive horses. For more information, visit

Contact Information:

Media Contact:
Marijane Funess
Crenshaw Communications for ZetrOZ, Inc.